Cargando…
Early Administration of the Phytocannabinoid Cannabidivarin Prevents the Neurobehavioral Abnormalities Associated with the Fmr1-KO Mouse Model of Fragile X Syndrome
Phytocannabinoids, including the non-addictive cannabis component cannabidivarin (CBDV), have been reported to hold therapeutic potential in several neurodevelopmental disorders (NDDs). Nonetheless, the therapeutic value of phytocannabinoids for treating Fragile X syndrome (FXS), a major NDD, remain...
Autores principales: | , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10416983/ https://www.ncbi.nlm.nih.gov/pubmed/37566006 http://dx.doi.org/10.3390/cells12151927 |
_version_ | 1785087910669713408 |
---|---|
author | Premoli, Marika Fyke, William Bellocchio, Luigi Lemaire, Valerie Wolley-Roberts, Marie Bontempi, Bruno Pietropaolo, Susanna |
author_facet | Premoli, Marika Fyke, William Bellocchio, Luigi Lemaire, Valerie Wolley-Roberts, Marie Bontempi, Bruno Pietropaolo, Susanna |
author_sort | Premoli, Marika |
collection | PubMed |
description | Phytocannabinoids, including the non-addictive cannabis component cannabidivarin (CBDV), have been reported to hold therapeutic potential in several neurodevelopmental disorders (NDDs). Nonetheless, the therapeutic value of phytocannabinoids for treating Fragile X syndrome (FXS), a major NDD, remains unexplored. Here, we characterized the neurobehavioral effects of CBDV at doses of 20 or 100 mg/kg in the Fmr1-knockout (Fmr1-KO) mouse model of FXS using two temporally different intraperitoneal regimens: subchronic 10-day delivery during adulthood (Study 1: rescue treatment) or chronic 5-week delivery at adolescence (Study 2: preventive treatment). Behavioral tests assessing FXS-like abnormalities included anxiety, locomotor, cognitive, social and sensory alterations. Expression of inflammatory and plasticity markers was investigated in the hippocampus and prefrontal cortex. When administered during adulthood (Study 1), the effects of CBDV were marginal, rescuing at the lower dose only the acoustic hyper-responsiveness of Fmr1-KO mice and at both doses their altered hippocampal expression of neurotrophins. When administered during adolescence (Study 2), CBDV at both doses prevented the cognitive, social and acoustic alterations of adult Fmr1-KO mice and modified the expression of several inflammatory brain markers in both wild-type littermates and mutants. These findings warrant the therapeutic potential of CBDV for preventing neurobehavioral alterations associated with FXS, highlighting the relevance of its early administration. |
format | Online Article Text |
id | pubmed-10416983 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2023 |
publisher | MDPI |
record_format | MEDLINE/PubMed |
spelling | pubmed-104169832023-08-12 Early Administration of the Phytocannabinoid Cannabidivarin Prevents the Neurobehavioral Abnormalities Associated with the Fmr1-KO Mouse Model of Fragile X Syndrome Premoli, Marika Fyke, William Bellocchio, Luigi Lemaire, Valerie Wolley-Roberts, Marie Bontempi, Bruno Pietropaolo, Susanna Cells Article Phytocannabinoids, including the non-addictive cannabis component cannabidivarin (CBDV), have been reported to hold therapeutic potential in several neurodevelopmental disorders (NDDs). Nonetheless, the therapeutic value of phytocannabinoids for treating Fragile X syndrome (FXS), a major NDD, remains unexplored. Here, we characterized the neurobehavioral effects of CBDV at doses of 20 or 100 mg/kg in the Fmr1-knockout (Fmr1-KO) mouse model of FXS using two temporally different intraperitoneal regimens: subchronic 10-day delivery during adulthood (Study 1: rescue treatment) or chronic 5-week delivery at adolescence (Study 2: preventive treatment). Behavioral tests assessing FXS-like abnormalities included anxiety, locomotor, cognitive, social and sensory alterations. Expression of inflammatory and plasticity markers was investigated in the hippocampus and prefrontal cortex. When administered during adulthood (Study 1), the effects of CBDV were marginal, rescuing at the lower dose only the acoustic hyper-responsiveness of Fmr1-KO mice and at both doses their altered hippocampal expression of neurotrophins. When administered during adolescence (Study 2), CBDV at both doses prevented the cognitive, social and acoustic alterations of adult Fmr1-KO mice and modified the expression of several inflammatory brain markers in both wild-type littermates and mutants. These findings warrant the therapeutic potential of CBDV for preventing neurobehavioral alterations associated with FXS, highlighting the relevance of its early administration. MDPI 2023-07-25 /pmc/articles/PMC10416983/ /pubmed/37566006 http://dx.doi.org/10.3390/cells12151927 Text en © 2023 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/). |
spellingShingle | Article Premoli, Marika Fyke, William Bellocchio, Luigi Lemaire, Valerie Wolley-Roberts, Marie Bontempi, Bruno Pietropaolo, Susanna Early Administration of the Phytocannabinoid Cannabidivarin Prevents the Neurobehavioral Abnormalities Associated with the Fmr1-KO Mouse Model of Fragile X Syndrome |
title | Early Administration of the Phytocannabinoid Cannabidivarin Prevents the Neurobehavioral Abnormalities Associated with the Fmr1-KO Mouse Model of Fragile X Syndrome |
title_full | Early Administration of the Phytocannabinoid Cannabidivarin Prevents the Neurobehavioral Abnormalities Associated with the Fmr1-KO Mouse Model of Fragile X Syndrome |
title_fullStr | Early Administration of the Phytocannabinoid Cannabidivarin Prevents the Neurobehavioral Abnormalities Associated with the Fmr1-KO Mouse Model of Fragile X Syndrome |
title_full_unstemmed | Early Administration of the Phytocannabinoid Cannabidivarin Prevents the Neurobehavioral Abnormalities Associated with the Fmr1-KO Mouse Model of Fragile X Syndrome |
title_short | Early Administration of the Phytocannabinoid Cannabidivarin Prevents the Neurobehavioral Abnormalities Associated with the Fmr1-KO Mouse Model of Fragile X Syndrome |
title_sort | early administration of the phytocannabinoid cannabidivarin prevents the neurobehavioral abnormalities associated with the fmr1-ko mouse model of fragile x syndrome |
topic | Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10416983/ https://www.ncbi.nlm.nih.gov/pubmed/37566006 http://dx.doi.org/10.3390/cells12151927 |
work_keys_str_mv | AT premolimarika earlyadministrationofthephytocannabinoidcannabidivarinpreventstheneurobehavioralabnormalitiesassociatedwiththefmr1komousemodeloffragilexsyndrome AT fykewilliam earlyadministrationofthephytocannabinoidcannabidivarinpreventstheneurobehavioralabnormalitiesassociatedwiththefmr1komousemodeloffragilexsyndrome AT bellocchioluigi earlyadministrationofthephytocannabinoidcannabidivarinpreventstheneurobehavioralabnormalitiesassociatedwiththefmr1komousemodeloffragilexsyndrome AT lemairevalerie earlyadministrationofthephytocannabinoidcannabidivarinpreventstheneurobehavioralabnormalitiesassociatedwiththefmr1komousemodeloffragilexsyndrome AT wolleyrobertsmarie earlyadministrationofthephytocannabinoidcannabidivarinpreventstheneurobehavioralabnormalitiesassociatedwiththefmr1komousemodeloffragilexsyndrome AT bontempibruno earlyadministrationofthephytocannabinoidcannabidivarinpreventstheneurobehavioralabnormalitiesassociatedwiththefmr1komousemodeloffragilexsyndrome AT pietropaolosusanna earlyadministrationofthephytocannabinoidcannabidivarinpreventstheneurobehavioralabnormalitiesassociatedwiththefmr1komousemodeloffragilexsyndrome |